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Abstract
Pre-exposure prophylaxis (PrEP) with anti-viral drugs is currently in clinical trials for the prevention of HIV infection.
Induction of adaptive immune responses to virus exposures during anti-viral drug administration, i.e., a ‘‘chemo-
vaccination’’ effect, could contribute to PrEP efficacy. To study possible chemo-vaccination, we monitored humoral and
cellular immune responses in nine rhesus macaques undergoing up to 14 weekly, low-dose SHIVSF162P3 rectal exposures. Six
macaques concurrently received PrEP with intermittent, oral Truvada; three were no-PrEP controls. PrEP protected 4
macaques from infection. Two of the four showed evidence of chemo-vaccination, because they developed anti-SHIV CD4
+
and CD8
+ T cells; SHIV-specific antibodies were not detected. Control macaques showed no anti-SHIV immune responses
before infection. Chemo-vaccination-induced T cell responses were robust (up to 3,940 SFU/10
6 PBMCs), predominantly
central memory cells, short-lived (#22 weeks), and appeared intermittently and with changing specificities. The two chemo-
vaccinated macaques were virus-challenged again after 28 weeks of rest, after T cell responses had waned. One macaque
was not protected from infection. The other macaque concurrently received additional PrEP. It remained uninfected and T
cell responses were boosted during the additional virus exposures. In summary, we document and characterize PrEP-
induced T cell chemo-vaccination. Although not protective after subsiding in one macaque, chemo-vaccination-induced T
cells warrant more comprehensive analysis during peak responses for their ability to prevent or to control infections after
additional exposures. Our findings highlight the importance of monitoring these responses in clinical PrEP trials and suggest
that a combination of vaccines and PrEP potentially might enhance efficacy.
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Introduction
Clinical trials are currently underway or are being completed to
evaluate the efficacy of pre-exposure prophylaxis (PrEP) with anti-
retroviral (ARV) drugs for the prevention of HIV infection
[1,2,3,4]. It is possible that HIV exposure during prophylaxis can
stimulate the immune system and induce adaptive immunity in the
absence of productive infection. This would be akin to the
observation that HIV-exposed, uninfected (EU) individuals can
harbor HIV-specific immune responses associated with protection
from infection ([5], and reviewed by Kulkarni et al. [6]). The effect
could be viewed as ‘‘chemo-vaccination’’, with natural HIV
exposures providing antigenic stimulation to the immune system,
while chemicals (ARVs) prevent or limit viral replication and
productive infection. A chemo-vaccination effect could be an
added benefit that contributes to the overall efficacy of PrEP, even
in individuals with low adherence to antiviral drug regimens.
Benefits of chemo-vaccination could include prevention of virus
acquisition, but also improved viral control should breakthrough
infections occur. Alternatively, immune activation due to virus
exposure during PrEP could raise susceptibility to HIV infection
by recruiting activated, HIV-specific CD4
+ target cells to mucosal
surfaces, thus potentially facilitating infection during subsequent
exposures [7,8] or increasing replication after virus transmission
[7,9]. It is therefore essential to understand if chemo-vaccination
can occur during PrEP and how this can modulate susceptibility to
infection. Non-human primate models of mucosal SIV or SHIV
exposure are ideal models to assess all these questions under highly
controlled conditions. The type and duration of immune responses
induced by PrEP during repeated mucosal virus exposures can also
be dissected in these models.
We have previously used rhesus macaques to closely model
human sexual HIV exposures [10] by repeatedly exposing
macaques at vaginal or rectal mucosal surfaces with low doses of
a CCR5-using SHIV strain. We subsequently employed this
repeat-low-dose (RLD) model to extensively test efficacy of various
ARV drugs in different PrEP schedules and doses under conditions
relevant to humans [11,12,13]. We now use the RLD model to
study adaptive immune responses induced by an intermittent PrEP
regimen with Truvada, a combination of the HIV-1 reverse
transcriptase inhibitors emtricitabine (FTC) and tenofovir dis-
oproxyl fumarate (TDF) [14]. The PrEP regimen was chosen to
model relevant scenarios for human clinical trials, rather than to
design ideal conditions for the priming of immune responses. We
find that SHIV-specific T cells, but not antibodies, appear
following virus exposures during PrEP. This confirmed earlier T
cell chemo-vaccination reports in nonhuman primates receiving
topical ARVs by others and us [13,15]. We expand these earlier
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before virus challenge and by establishing a cut-off for positive
responses elicited by chemo-vaccination based on pre-exposure
baseline responses. Furthermore, we now dissect the time course of
anti-SHIV T cell appearance and disappearance, their epitope
specificity, CD4/CD8 composition, and ability to produce
multiple cytokines. Moreover, using a macaque model allowed
us to re-challenge a subset of the macaques after completion of
PrEP to directly test for protective effects of immune responses.
Results
Repeated mucosal virus exposures and intermittent, oral
PrEP
We sought to determine whether a relevant intermittent PrEP
regimen designed for human application induces T cell immunity.
Figure 1 outlines the study protocol used to model human sexual
transmission of HIV during PrEP, and indicates outcome of viral
exposures. We used the RLD rectal SHIV-exposure macaque
model and a partially effective PrEP regimen of intermittent, oral
Truvada administration [16]. Four PrEP-treated macaques
remained uninfected, while two were infected after 4 and 14
rectal SHIV exposures, respectively. The three untreated control
macaques became infected after 1, 3, or 5 exposures, consistent
with previous findings in 29 additional controls receiving the same
virus-only rectal treatment [16]. Compared to a total of 32
untreated controls, the PrEP regimen reduced the risk of infection
by 9.3-fold (p=0.003) [16].
Enumeration of SHIV-specific T cells elicited by chemo-
vaccination during and after repeated SHIV exposures
During 14 initial virus exposures and 27 weeks of follow-up, we
enumerated SHIV-specific T cells in peripheral blood by IFNc-
ELISPOT, using 14 SHIV-derived peptide pools to stimulate fresh
PBMCs. Before antigen exposure, in study week 0, the combined
T cell response directed at these antigen pools ranged from 0
(animals 35451, 33756, 35032) to 355 SFU/10
6 PBMCs (animal
35720) (Fig. 2A–D), with a mean 73 SFU/10
6 PMBCs. To
discriminate positive T cell responses from background, we used a
cut-off value of 417 SFU/10
6 PMBCs, equal to all animals’ mean
value in week 0 plus 3 standard deviations. T cell responses above
this cut-off in the absence of productive SHIV infection were
defined as evidence for chemo-vaccination. Two of the four PrEP-
protected macaques developed T cell responses during the 14
weeks of virus challenges (35451 and 4284) (Fig. 2A, B), and
therefore showed evidence of chemo-vaccination. The first
responses in macaques 4284 and 35451 were observed during
week 7, after the macaques had already received 6 virus exposures.
The responses increased over time, reaching a peak 3940 SFU/
10
6 PBMCs (4284) in week 14, or 2930 SFU/10
6 PBMCs (35451)
Figure 1. Experimental Design. SHIV-specific T cells were measured during the indicated experimental procedures. Arrows indicate repeated viral
exposures, horizontal lines depict intermittent, oral PrEP. PrEP consisted of human-equivalent doses of oral Truvada. Each virus exposure was flanked
by a waning drug dose of 7 days prior, and one drug dose administered 2 hours after exposure, as a model for intermittent PrEP use in humans.
Bolded rectangles highlight final outcomes of SHIV challenges. Numbers in lower right corners refer to macaque identifications (IDs).
doi:10.1371/journal.pone.0019295.g001
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19295Figure 2. Chemo-vaccination effect. SHIV-specific T cells are induced in two PrEP-protected macaques during PrEP and virus exposures. PrEP
protected four macaques from infection during 14 SHIV exposures in weeks 1–14 (A and B), while two became infected despite PrEP (C); three
macaques were controls (D). SHIV-specific T cells were determined by IFNc-ELISPOT. The black bars represent the number of specific T cells as a sum
of responses to 14 SHIV-derived peptide pools for antigenic simulation, measured in SFU (spot forming units, left axis). Grey lines depict plasma
viremia (right axes). The graphs represent data from individual macaques, their identification codes are bolded. The dotted lines are cut-off values for
positive T cell responses. Two PrEP-protected macaques (35451 (A), 4284 (B)) showed signs of chemo-vaccination. During re-challenge with 14 SHIV
exposures in weeks 42–55, additional PrEP protected macaques 35451 and 33756 (A). Chemo-vaccinated macaques 4284 and 33246 were not
protected from SHIV infection (B). Throughout the study, anti-SHIV antibodies were determined every 6 weeks (weeks 1–41) or 4 weeks (weeks 42–
69). ‘‘Y’’ indicates time of seroconversion.
doi:10.1371/journal.pone.0019295.g002
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were detectable in weeks 7, 9, 12, and 14, but not 11 and 13 in
macaque 4284, and similarly detectable in weeks 7, 9, 13, but not
11, 12, and 14 in macaque 35451.
To better understand the longevity of the T cell responses seen
in the two chemo-vaccinated macaques, we continued to monitor
IFNc-producing cells intermittently for up to study week 41, 27
weeks after the last virus challenges. Figure 2B shows that
macaque 4284 still had SHIV-specific T cells at weeks 19 and 36,
but not at week 41. Macaque 35451’s T cell responses were only
examined at weeks 19 and 36, and responses were only detectable
at week 19 (Fig. 2A). Thus, the minimal documented T cell
longevity was 22 and 5 weeks after last antigen exposure,
respectively. Due to the low assay frequency, it is possible that T
cells persisted longer, but they had definitively subsided within 27
and 22 weeks of last antigen exposure in both macaques.
Two macaques, 35032 and 34912, became infected after 3 or 14
virus exposures, respectively, despite PrEP (Fig. 2C). Macaque
35032 showed no T cell responses during exposures, but
developed them after infection as expected. In contrast, macaque
34912 had one response at week 13 before SHIV infection, and
thus displayed chemo-vaccination effects according to our
definition. The response was weak (585 SFU/10
6 PBMCs). Thus,
taken together, three of the six PrEP-treated macaques had
chemo-vaccination-induced T cells at least once during the trial.
The T cell response of 34912 was present three weeks before viral
RNA was first detected in week 16, indicating that the weak T cell
response did not prevent infection. Control macaques had no
SHIV-specific T responses prior to their infection after 1, 3, or 5
exposures, as previously observed in an exposed, uninfected
macaque, and in several macaques infected late during 14
repeated rectal exposures [17]. After infection, control macaques
developed T cell responses as expected (Fig. 2D). Responses
peaked at 4405, 2725, and 2770 SFU/10
6 PBMCs at weeks 7, 15,
13, respectively, with absolute numbers that were similar to the
chemo-vaccination levels of the exposed but uninfected macaques.
In contrast to T cell immunity, SHIV-specific binding
antibodies appeared only as a result of SHIV infection, but not
following chemo-vaccination in the absence of infection. Serocon-
version happened within up to 4 weeks of infection and the
development of T cell responses (as indicated by the letter ‘‘Y’’ in
Figure 2). PrEP-protected, chemo-vaccinated macaques did not
have anti-SHIV antibodies when analyzed in weeks 12, 14, 20,
and 40 (data not shown).
Rapidly changing epitope specificity of T cells elicited by
chemo-vaccination during and after SHIV exposures
The relative contribution of each of the 14 peptide pools to the
overall T cell response changed in chemo-vaccinated macaques
4284 and 35451 during virus exposures and concurrent PrEP
(Fig. 3A). For example, in macaque 4284, the most dominantly
recognized peptide pools changed from pol 2Rpol 4Rpol 1Rpol
5 in weeks 7, 9, 12, and 14, respectively. In contrast, specificities in
infected control macaques remained more stable during a similar
time frame (Fig. 3A, macaques AG94, AI22, 35720). For example,
in control macaque AG94, T cells underwent one early shift in
focus from the nef to the env 2 peptide pool, but then remained
focused on env 2 throughout the study.
We addressed whether chemo-vaccination-induced T cells had
different epitope specificities than T cells induced during SHIV
infection. In chemo-vaccinated, PrEP-protected macaques, a
mean 54% of activated T cells were directed towards pol
sequences during 41 weeks of virus exposures and follow-up,
compared to only 24% in macaques infected during PrEP or as
controls (p,0.0001, Fig. 3B). A focus on pol was also observed on
the one occasion of T cell responses in PrEP-treated macaque
34912 before its infection, as is indicated in Fig. 3B. In
comparison, only 28% of 34912’s T cells recognized pol epitopes
on the last time point of T cell analysis (study week 28) after SHIV
infection (Fig. 3B, and data not shown). Only 12% and 16% of the
T cells in chemo-vaccinated macaques focused on gag and env,
respectively, while 20% and 35% were focused on gag and env in
infected PrEP-treated or control macaques (p=0.0388 and
p=0.0002 for gag and env, respectively). Thus, chemo-vaccina-
tion-induced anti-SHIV T cells indeed had a shifted epitope focus
compared to productive SHIV infection.
Cytokine production by CD4
+ and CD8
+ T cells associated
with chemo-vaccination during and after SHIV exposures
To analyze functional properties of PrEP-induced T cells, we
tested their ability to produce intracellular IL-2, MIP-1b, TNFa,
and IFNc. The two dominantly recognized peptide pools at each
time point were determined by ELISPOT, and were then used to
optimally stimulate T cells. Figure 4A depicts the number of T
cells with intracellular induction of IL-2, MIP-1b, TNFa, or IFNc
from all of the macaques (chemo-vaccinated/uninfected, or
infected during PrEP or as controls). Chemo-vaccination induced
cytokine-producing T cells in similar numbers as SHIV infection
of controls or PrEP-breakthrough macaques, indicating that
chemo-vaccination-induced T cells are functional with regards to
cytokine production. Macaque 34912’s T cells showed no selective
inability to produce cytokines before it became infected, indicating
that the lack of protection from subsequent infection was not due
to inability to produce cytokines. In Figure 4B, a representative
graph displays the induction of cytokine-production by peptide or
superantigen-stimulation in cells from 34912. Antigen stimulation
resulted in substantial increases in intracellular production of all
the four factors. A fraction of T cells were also able to
simultaneously produce cytokines (data not shown, and see below).
SHIV-specific, cytokine-producing T cells in blood consisted of
both CD4
+ and CD8
+ T cells in chemo-vaccinated macaques
4284, 35451, and in 34912 before infection (Fig. 4C). Macaque
34912 had no unusual expansion of CD4
+ blood cells which could
have provided a larger pool of infection target cells (Fig. 4C),
suggesting that a greater availability of susceptible CD4
+ cells was
not the cause of subsequent infection.
Re-challenge of previously PrEP-protected macaques
with SHIV; enumeration of anti-SHIV T cells and their
epitope specificities
After 41 weeks of study, when SHIV-specific T cell activities
had subsided to undetectable levels in blood, the four PrEP-
protected, uninfected macaques were enrolled into another PrEP
trial that evaluated the impact of drug resistance on PrEP efficacy
[14] (Fig. 1). In the subsequent trial, the animals received a second
round of SHIV exposures 28 weeks after they were last exposed in
the previous study, and we examined whether a history of SHIV
exposures, PrEP, and/or T cell responses altered the outcome of
additional SHIV challenges.
Two of the macaques (4284 and 33246) were enrolled into a
control arm receiving no further PrEP during 14 additional RLD
challenges using SHIVSF162P3-M184V. The other two macaques
(35451 and 33756) were virus challenged while receiving PrEP with
Truvada. Each of the study arms included one macaque with and
one without a history of previous SHIV-specific T cells (Fig. 1, 2).
Both control macaques became infected (Fig. 2B). These 2
macaques (4284, 33246) were identical at 8 Mamu alleles known
Chemo-Vaccination by SHIV Exposure during PrEP
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19295Figure 3. Epitope specificity of T cells induced by chemo-vaccination. A: T cell specificities in PrEP-protected macaques 4284 and 35451
change rapidly during SHIV exposures and PrEP, while they remain more consistent in infected control macaque AG94, and in 4284 after infection. T
cell specificities were determined by IFNc-ELISPOT with 14 peptide pools represented by the indicated colors. The pie charts depict percentages of
contributions to the T cell response. Arrows indicate time point of virus exposures, adjacent numbers indicate how many exposures were given.
Seroconversion is recorded by ‘‘Y’’; numbers indicates the study week of seroconversion. B: T cells induced by chemo-vaccination appear focused on
epitopes derived from the pol region. IFNc-ELISPOT responses to 14 peptide pools were combined for the indicated gene products; their contribution
to the response (all 14 peptide pools) was calculated. All IFNc-ELISPOT results from week 1–41 are depicted. N refers to number of macaques in the 4
specified groups. P-values were obtained by unpaired, two-sided student’s t-tests comparing all results before infection (12 time-points from 3
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Macaque 4284, with a history of T cell responses up to week 36,
but no responses thereafter, became infected after 3 virus
exposures. Macaque 33246 without any previous SHIV-directed
T cells was infected after 10 exposures. Infections after 3 and 10
exposures are within the normal range of exposure-naı ¨ve animal
infections with this virus strain [14]. The history of SHIV-specific
T cells in this animal, therefore, did not protect from or accelerate
virus acquisition at this time-point, when T cell responses had
subsided. The two macaques had remarkably similar levels of
viremia (Fig. 2B), which peaked at 5.0 or 5.5610‘6 viral copies/
mL in blood in 4284 and 33246, respectively.
Neither of the two animals in the PrEP/SHIV exposures arm
became infected (Fig. 2A). The virus exposures during PrEP again
induced SHIV-specific T cell responses in chemo-vaccinated
35451, but still none in macaque 33756 (Fig. 2A). Thus, macaque
33756 received 28 SHIV exposures and remained uninfected, but
did not exhibit any SHIV-specific blood T cells in 25 independent
assays. In macaque 35451, which similarly received 28 SHIV
exposures and remained uninfected, T cell responses were not
easily re-called, and only became detectable in blood after 10
additional virus exposures.
T cells were detected intermittently during virus exposures, as
observed after the first 14 SHIV exposures. In macaque 35451,
anti-SHIV responses were detected at weeks 52 and 54, but not
55, followed by consistent detection in the follow-up phase (weeks
57–69). T cell epitope focus continued to shift between detection
times (Fig. 3A).
T cell differentiation parameters in chemo-vaccinated
macaque 35451
Macaque 35451 was the most extensively chemo-vaccinated
macaque in our study. We further dissected epitope specificity and
differentiation parameters in this macaque (Fig. 5). The number of
peptide pools recognized over the entire study is shown in Fig. 5A.
Epitope diversity appeared similar during and following re-
challenge (challenges 15–28), because an average 4.9 peptide
pools were recognized with more than 10% of the total T cells
during weeks 52–69, compared to an average 4.4 pools in weeks
7–19. The relative contribution of pol-, env-, and gag-specific T cells
chemo-vaccinated macaques, filled circles and open diamonds combined) to those after infection (56 time-points from 5 macaques in control or
PrEP-infected groups, open circles and filled triangles combined).
doi:10.1371/journal.pone.0019295.g003
Figure 4. Cytokine production of CD4
+ and CD8
+ T cells induced by chemo-vaccination. Intracellular production of IFNc, IL-2, MIP-1b,o r
TNFa was measured by flow cytometry after in-vitro incubation of freeze-thawed cells with the two dominant peptide pools as determined by
previous IFNc-ELISPOT. We gated on CD3
+ and CD69
+ (A, B), or on CD3
+, CD69
+, and CD4
+ or CD8
+ (C), and determined the number of cells with
intracellular production of any of the factors, regardless of whether they simultaneously produced the remaining 3 factors. ‘‘Any’’ refers to cells
producing any of the indicated factors, not necessarily all simultaneously. Samples from infected controls or infected PrEP-treated macaques were
from peak viremia or 6 weeks thereafter, whenever available. Such samples are not shown for CD4/CD8 analysis, because CD4
+ cells significantly
decline depending on the stage of SHIV infection. (B) Representative example of results obtained with cells from macaque 34912 before its infection,
without stimulation (‘‘no stim.’’), with the two dominant peptide pools, or with SEB for polyclonal stimulation.
doi:10.1371/journal.pone.0019295.g004
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uninfected macaque remained largely focused on epitopes in pol
gene products, but the average contribution to the T cell response
was now only 33% in weeks 52–69, compared to 42% in weeks 7–
19. To further study T cell differentiation, we analyzed whether
simultaneous production of multiple cytokines increased, as
happens during functional T cell maturation. We determined
the percentage of SHIV-specific T cells producing all four
measured factors simultaneously, or any 3 or 2 of them
simultaneously (Fig. 5C). The percentage of anti-SHIV T cells
producing all four measured factors (IFNc, TNFa, MIP-1b, and
IL-2) simultaneously increased slightly from an average 3% in
weeks 7–19 to 5% in weeks 52–69, while cells producing any of
these factors alone decreased slightly from 75 to 66%. T cell
differentiation can also be examined by analyzing contributions of
cytokine-producing effector memory (TEM=CD3
+ CD69
+ [IFNc,
TNFa, MIP-1b, and/or IL-2]
+, CD28
high/low, CCR7
2) and
central memory (TCM=CD3
+ CD69
+ [IFNc, TNFa, MIP-1b,
and/or IL-2]
+, CD28
high, CCR7
+) cells using flow cytometric
methods [18]. Anti-SHIV CD4
+ and CD8
+ T cells were
predominantly TCM cells at all time points following chemo-
vaccination in macaque 35451 (Fig. 5D shows flow cytometry data
for select time points, and Fig. 5E displays results for all time
points), and also in macaque 4284 (data not shown). The
contribution of TEM (transitional TEM1 and fully differentiated
TEM2 populations combined) to anti-SHIV CD4
+ or CD8
+ T cells
rose slightly from 11% to 19% in weeks 7–19 compared to weeks
52–69, respectively, in macaque 35451.
Anti-SHIV T cells were still detectable in week 69 in macaque
35451, 14 weeks after last virus challenge, but no longer in study
weeks 75 and 81 (Figure 2). Thus, longevity was again limited, and
declined to undetectable levels within 20 weeks after last virus
challenge.
Discussion
We show that PrEP with anti-retrovirals can facilitate the
development of adaptive T cell immunity in response to mucosal
virus exposures. This ‘‘chemo-vaccination’’ effect was documented in
detail by analyzing incidence, duration, epitope specificities,
functional properties, differentiation markers, and protective effects
of T cells. This confirms earlier chemo-vaccination reports either
during pre-exposure prophylaxis [15,13], or following effective anti-
retroviral treatment begun shortly after inoculation [19]. We
significantly expanded on earlier studies by using a cut-off for positive
anti-viral T cell responses based on background measurements in
naı ¨ve animals. This allowed us to demonstrate that chemo-
vaccination-induced T cell responses are not merely pre-existing
backgroundresponseswithcross-reactivitytoSHIV-derivedantigens.
Chemo-vaccination induced anti-SHIV T cells in two of four
PrEP-protected macaques, and in one of two macaques before they
failed PrEP. One reason for the incomplete response rates could be
variations in viral antigen presentation in individual macaques, e.g.,
dueto MHC allelic variability. It is noteworthy that macaque35451
with strong T cell responses was the only study macaque harboring
Mamu-B08, an allele associated with superior control of SIV [20].
The other macaque with chemo-vaccination-induced T cells (4284),
on the otherhand,was not unique initsgeneticMHCmake-up.Itis
possible that T cell responses developed, but were not detected in all
macaques, due to different induction kinetics, trafficking behavior,
or compartmentalization.
A major limitation was the small number of animals at the
beginning of the study, and further subdivision of animals due to
different experimental outcomes. Only one animal with anti-SHIV
T cells could be re-exposed to virus, and only when its T cell
responses had subsided. Nevertheless, the in-depth description of
chemo-vaccination and long follow-up time in this study provide
useful information for future study designs to further examine
incidenceand consequences of chemo-vaccination in macaques and
inlimitedsamplesfrom humanclinical PrEP trials.In future studies,
it would also be worthwhile to comprehensively evaluate mucosal
specimens, and tissue- or lymphatic tissue-resident lymphocytes.
We characterized chemo-vaccination induced T cells. Life-span
of the cells was limited to less than 27 weeks, while memory T cells
induced by potent vaccines or infection can last for years if not a
lifetime [21]. Re-stimulation of previously expanded T cells
appeared impaired, because dominant epitope specificities changed
rapidly. This suggests that immune memory qualities were not well
developed. Memory T cells were mostly of TCM phenotype, while
superior protection from and control of SIV by mucosal TEM cells
has been reported [18]. Lastly, we noticed a focus on pol epitopes,
rather than env and gag. Anti-pol immune-reactivity can be effective
[22], but efficient viral control is better documented for gag –
directed T cells [23]. It is noteworthy that a study in HIV
+
individuals exposed to other HIV strains by their HIV
+ partners,
but not super-infected, also found T cells focused on pol products
[24]. In addition, dominant T cell responses to pol rather than env
have been reported for EU individuals [25]. Focus on pol might
therefore be a feature of T cells elicited by priming in the absence of
productive infection. It is possible that different tests for T cell
differentiation and function (e.g., for proliferative or cytotoxic
capabilities) would have revealed additional T cell characteristics,
but no additional specimens were available for such analyses.
The high frequency of virus exposures likely prevented efficient
functional T cell memory maturation and survival. It is important
to emphasize, however, that the study was not designed to
optimally induce T cell immunity. Rather, we addressed what kind
of immunity is induced by physiologic virus exposures concurrent
with partially effective PrEP. Thus, we consider our results
relevant for the type of T cell immunity that can be expected
following an intermittent PrEP regimen in sexually active people.
Having a history of SHIV-specific T cells due to chemo-
vaccination did not protect macaque 4284 from SHIV infection,
nor did it delay or significantly accelerate its infection. Ensuing
viremia was remarkably similar in another re-challenged macaque
(33246), although 33246 had never shown anti-SHIV T cell
responses. Both macaques were identical at eight MHC alleles
known to impact viral control. Limitations of these studies include:
Only one animal was tested, and re-exposure occurred when
peripheral blood virus-specific T cells had waned. Another
macaque, 34912, became infected after 14 viral exposures, despite
weak T cell responses after the 13
th exposure. It is unclear whether
the animal was already in the viral eclipse phase when T cells were
detected. Further research is needed to determine a potentially
increased or decreased infection risk after chemo-vaccination
during subsequent virus exposures.
T cells matured further in macaque 35451 after resting and
undergoing more chemo-vaccination, but it is not clear whether
minor changes in epitope specificities and memory phenotype
significantly affected anti-viral functions. Chemo-vaccination-
induced T cell immunity could possibly be improved by
combining PrEP with a vaccine targeted to induce specific
immune pathways. A complex vaccine with an antibody-inducing
component could complement the observed lack of antibodies;
another component could accelerate limited TEM differentiation.
Deliberately skewing T cells towards TEM phenotype would most
likely also increase mucosal anti-viral responses [18,21]. Moreover,
the RV144 HIV vaccine trial suggested that vaccine efficacy may
Chemo-Vaccination by SHIV Exposure during PrEP
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19295Figure 5. Epitope specificity and differentiation parameters of anti-SHIV T cells in chemo-vaccinated macaque 35451. A: Number of
recognized peptide pools: As a measure of the breadth of T cell diversity, the number of peptide pools recognized was examined. Only pools
recognized with 10% or more of the anti-SHIV T cell ELISPOT response are shown. B: Contributions of epitopes in pol, env, gag: T cells to
products of pol, env, and gag are depicted as percentage of the total IFNc-ELISPOT response. C. Ability to simultaneously produce multiple
cytokines/chemokines. Intracellular production of IFNc, TNFa, MIP-1b, and/or IL-2 (‘‘factors’’) was measured by flow cytometry after gating on
CD3
+ CD69
+ cells. Freeze-thawed PBMCs were cultured with 2 dominant peptide pools as determined by ELISPOT for each time point. We determined
the number of cells that produced any of the factors (‘‘responders’’), and then analyzed whether the cells made any one factor alone, any two or three
factors, or all four factors simultaneously. D. Gating strategy for determination of anti-SHIV effector and central memory T cells (TEM and
TCM, respectively). Cells were stimulated as described in C. For the indicated control analyses, CD3
+ gated cells were analyzed for CD28 or CCR7
expression, thus defining transitional TEM1,T EM2, and TCM quadrants for samples analyzed on the same day, i.e. from weeks 7 or 19 (control 1) or from
week 69 (control 2). The same quadrants were applied to anti-SHIV T cells (CD3
+, CD69
+, and [IFNc
+, TNFa
+, MIP-1b
+, and/or IL-2]
+), after further
gating on CD4
+ or CD8
+ cells. The numbers in the upper right quadrants refer to TCM cells as percentage of anti-SHIV CD4
+ or CD8
+ cells. E: TEM (TEM1
and TEM2) and TCM cells are shown as percentage of anti-SHIV T cells (CD4
+ or CD8
+ cells), as determined by flow cytometry described in C
and D. Arrows indicate virus exposures, horizontal bars depict PrEP treatment.
doi:10.1371/journal.pone.0019295.g005
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vaccine is administered prior to PrEP, chemo-vaccination could
possibly boost and extend limited vaccine efficacy. Thus,
combination of these two HIV prevention methods could have
additive or synergistic effects and raise their combined efficacy
significantly. These issues could be addressed by further research
in nonhuman primate models employing comparative groups of
single or combined prevention modalities, administered during
controlled virus exposures.
Anti-SHIV T cells were composed of CD4
+ and CD8
+ cells,
suggesting that antigen presentation likely occurred in MHC class
I and II pathways. It is possible that antigen presentation was
mostly the result of uptake of virus particles by resident antigen
presenting cells through endocytic mechanisms. Many experimen-
tal SHIV stocks contain a large proportion of replication-defective,
non-infectious, or severely attenuated virions; these may induce
immune responses by this mechanism. We previously found no
anti-SHIV T cell responses in macaques exposed rectally up to 14
times to virus without concurrent PrEP [17], although they have
been observed after vaginal exposure [27]. It is possible that PrEP-
treated macaques experienced a low level of initial virus
replication that remained local, and did not result in systemic
infection due to the anti-retroviral action of Truvada. Because the
PrEP regimen was partially effective, and did not block infection in
all macaques, there may have been more transient/abortive
infection than during highly effective PrEP, resulting in stronger
induction of immune responses, as has been documented in earlier
PrEP studies of perinatal SIV infection by Van Rompay et al [28].
Even if initial local replication occurred, it likely did not persist in a
suppressed state, because we did not detect it using three assays
(detection of plasma viral RNA load, proviral DNA in PBMCs,
and serum anti-SHIV antibodies) during extended follow-up (data
not shown). In addition, we previously reported no evidence for
occult infection in similarly PrEP-protected macaques after in-vivo
depletion of CD8
+ T cells [29].
It is not clear why chemo-vaccination induced no B cell
immunity despite considerable T cell immunity. B cell induction
requires CD4
+ T cell help. High-avidity memory CD4
+ T cells are
induced by more prolonged antigenic stimulation than CD8
+ cells
[30]. It is possible that chemo-vaccination-induced anti-SHIV
CD4
+ T cells did not differentiate enough to become efficient B
cell helpers. Alternatively, viral antigens possibly did not reach
lymphoid tissues necessary for B cell maturation [31]. Mucosal
secretions were not tested for the presence of anti-viral antibodies,
and it is therefore possible that mucosal but not systemic
antibodies were induced by chemo-vaccination. In addition, low-
level SHIV-specific antibodies may have been below the limit of
detection of the Bio-Rad 1/2 plus O EIA assay, although this assay
is considered more sensitive than commercial Western Blotting
techniques for the diagnosis of sero-conversion.
It is currently unclear whether human iPrEx [4] or other PrEP
trial participants experienced chemo-vaccination effects and
whether this is impacted by HIV exposure frequency. Exposure
interval effects have been observed in EU commercial sex workers,
including a group who lost T cell responses after taking a 2-month
or longer break from sex work [5]. Potential protection associated
with chemo-vaccination could be determined when individuals are
retrospectively grouped into HIV-reactive and non-reactive PrEP
participants. Given the variations in human behavior and HIV
exposure, however, nonhuman primate models have great
advantages for further study of the consequences of chemo-
vaccination. Animals can be sampled very frequently; in contrast,
in clinical trials, the larger intervals between visits make it more
likely that chemo-vaccination effects are missed.
In conclusion, intermittent Truvada-based oral PrEP regimens
can facilitate induction of T cell immunity following repeated virus
exposure. Occurrence and implications of such chemo-vaccination
effects should be evaluated in specimens from current human
PrEP trials. We suggest that combination of PrEP and vaccines
might be more efficacious than either intervention alone. Such
studies can be informed by comprehensive examination of
immune responses and outcomes of vaccines, PrEP, microbicides,
and other combination approaches aimed at interrupting HIV
transmission.
Materials and Methods
Ethics statement
The Institutional Animal Care and Use Committee (IACUC) of
the Centers for Disease Control and Prevention (CDC) approved
all macaque procedures described (protocol permit numbers:
1414OTTMONC, 1615GARMONC, 2099GARMONC). This
study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health (NIH) and with the recommen-
dations of the Weatherall report, ‘‘The use of non-human primates
in research’’. All procedures were performed under anesthesia
using ketamine, and all efforts were made to minimize suffering,
improve housing conditions, and to provide enrichment opportu-
nities (e.g., objects to manipulate in cage, varied food supplements,
foraging and task-oriented feeding methods, interaction with
caregivers and research staff).
Macaques, virus, and repeat-low dose (RLD) virus
challenges
Nine adult, male Indian rhesus macaques were housed at CDC.
The genetic identity of eight MHC alleles with potential impact on
SHIV susceptibility and infection course were (macaque ID
number, identified alleles): 35451: B08; 33756: A01, A02; 4284:
A08; 33246: A08; 35032: none of the above; 34912: A08, B17;
AG94: A08; AI22: B01; 35720: A01, A08, B17 (evaluated at the
University of Wisconsin AIDS Vaccine research laboratory).
SHIVSF162P3 (SIVmac239 backbone plus HIV-1 B env) [32,33]
was provided by the NIH AIDS Research and Reference Reagent
Program (NARRRP, catalog #6526). SHIVSF162P3 infection is
typically accompanied by T and B cell responses [29,34], thus
allowing us to study formation of such responses during PrEP. All
macaques underwent up to 14, once-weekly, rectal SHIVSF162P3
exposures at a low dose of 10 TCID50 per exposure as published
elsewhere [16]. The dose equaled 7.6610
5 RNA copies, which is
in the range of HIV-1 RNA amounts in human semen (10
3–10
6
viral copies per milliliter) during acute infection [35]. Virus
exposures were stopped when a macaque became SHIV RNA-
positive. Procedures for blood collection, and determination of
SHIV infection with three methods (quantitation of viral
RNA$50 copies/mL plasma, serum anti-HIV antibody and
proviral DNA determination) have been published [12,16]. The
HIV-1/HIV-2 plus O EIA (BioRad/Genetic Systems, Redmond,
WA) antibody detection kit was utilized to determine time-point of
seroconversion, using the cut-off criteria set forth by the
manufacturer. This assay can detect both IgG and IgM, resulting
in a higher sensitivity during early infection than commercial
Western Blotting assays. It contains these antigens: recombinant
HIV-1 gp160 (env) and p24, a Group O gp41 (env) peptide, and a
gp36 (env) peptide from HIV-2. Since SHIVSF162P3 contains HIV-
1-env, infected monkeys show HIV-1-env reactivity. In addition,
there is a large amount of cross reactivity between antibodies to
p27 from SIV/HIV-2 and HIV-1 p24. After a washout period of
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efficacy study that evaluated the impact of the M184V mutation
associated with FTC resistance on PrEP efficacy. These 4 animals
were exposed rectally to SHIVSF162P3-M184V under the same
conditions and using the same inoculation protocol. The dose of
virus was increased to 40 TCID50 to account for a reduced
transmissibility associated with M184V [14]. The M184V
mutation is not expected to significantly affect overall anti-SHIV
T cell responses, because it only alters one potential T cell epitope
in pol gene products.
Intermittent PrEP regimen. Six macaques received
human-equivalent doses of Truvada (22 mg/kg of TDF and
22 mg/kg of Emtricitabine FTC) by oral gavage seven days before
viral challenge and 2 hours afterwards, and then once a week,
2 hours after each virus exposure. Thus, each virus exposure was
flanked by a waning drug dose of 7 days prior, and one drug dose
administered soon after exposure, a potential scenario for
intermittent PrEP use in humans. Three additional macaques
did not receive drug and were used as controls. The efficacy of the
PrEP regimen and the kinetics of infection in breakthrough
animals have been reported elsewhere [16].
T cell analyses by IFNc-ELISPOTs. PBMC were enu-
merated with an automated Guava cell counter (Millipore,
Billerica, MA). We enumerated SHIV-specific T cells by IFNc-
ELISPOTs, incubating fresh cells for 36 hours with the following
peptide pools (15-mers with 11 amino acid overlaps) at a final
concentration of 1.5 ug/ml: SIVmac239-pol (pol 1: peptides 1–50;
pol 2: peptides 51–100; pol 3: peptides 101–150; pol 4: peptides
151–200; pol 5: peptides 201–263, NARRRP # 6443); HIV-1
consensus B-tat (NARRRP #5138), and SIVmac239-nef, vpr, or
vif (NARRRP # 8762, 6449, 6205). Two SIVmac239-gag, 3
SHIVSF162P3-env pools, Staphylococcus aureus Enterotoxin (SEB,
positive control) and a mock peptide pool (negative control) have
been previously described [17]. Results were read on a S5 Core
Analyzer (Cellular Technology Ltd, Shaker Heights, OH). The
number of SHIV-specific T cells responding to each peptide pool
was determined as SFU/10‘6 PBMC after subtracting the values
for the mock peptide pool.
Statistical Methods. We established a strict cut-off value for
IFNc ELISPOTs to discriminate background variations from
SHIV-specific T cells. This consisted of baseline T cell reactivity in
the 9 virus-naı ¨ve macaques, cumulative of responses to all 14
peptide pools, plus 3 standard deviations (417 SFU/10
6 PBMC).
To analyze epitope specificity, the relative contribution of gag
(pools 1+2), env (pools 1-3), pol (pools 1-5), tat, nef, vpr,o rvif pools to
the combined T cell response (all peptide pools) was calculated.
Statistical analyses of epitope specificities were performed using
unpaired, two-sided student’s t-tests on results from groups of
macaques (e.g. PrEP-treated uninfected macaques compared to
infected macaques).
Flow cytometry. Prior to flow cytometry, PBMCs were
frozen and thawed as described [17]. For intracellular cytokine
analysis and effector and central memory T cell determination
(TEM and TCM) based on cytokine expression [18], we washed
cells twice, and incubated them with their two dominant peptide
pools (as determined by ELISPOT) at 1.5 ug/mL and Golgi-plug
kit (BD Biosciences, San Jose, CA) for 6 hours. Antibody staining
(clone names in parentheses, all from BD Biosciences, San Jose
CA, unless otherwise stated) was performed with anti-CD3 (SP34-
2), -CD4 (L200, NIH Nonhuman Primate Reagent Resource), -
CD8 (SK1), -CD69 (L78), -CCR7 and -MIP-1b (unnamed, and
D21-1351, R&D Systems Minneapolis, MN), -CD28 (CD28.2), -
IL-2 (MQ1-17H12), -TNFa (MAB11), -IFNc (B27). Samples were
examined on a LSRII flow cytometer (BD Biosciences, San Jose,
CA), and analyzed using FlowJo software 7.2.1 (Tree Star, San
Carlos, CA). To analyze cytokine production quantitatively, we
counted total lymphocytes/mL fresh blood, measured percentages
of cytokine
+ cells in thawed lymphocytes/mL of blood, and then
calculated numbers of cytokine
+ cells/mL blood. For quantitative
TEM and TCM analysis, we gated on CD3
+ and CD69
+ cells. We
then enumerated cytokine producing cells (making IFNc, TNFa,
MIP-1b, and IL-2 alone or simultaneously in any combination) as
described above. TCM cells were defined as CD3
+ CD69
+ (IFNc,
TNFa, MIP-1b, and/or IL-2)
+, CD28
high, CCR7
+; while TEM1
cells were CD3
+ CD69
+ (IFNc, TNFa, MIP-1b, and/or IL-2)
+,
CD28
high, CCR7
2; and TEM2 cells were CD3
+ CD69
+ (IFNc,
TNFa, MIP-1b, and/or IL-2)
+, CD28
low, CCR7
2. Gates for TEM
and TCM cells were set based on CD28 and CCR7 expression in
control analyses of all CD3
+ cells, regardless of their cytokine-
production status.
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